Abera har den senaste tiden beviljats forskningsstöd om totalt upp till cirka 11 MSEK.
Redeye comments on Lifecare following today’s news that the company has completed a key development ...
Scientific advisory meetings with country-level EU authorities Market research shows payer interest ...
Redeye sees a solid Q3 report from Hanza, especially given the circumstances.
Higher occupancy and positive net letting Clearly outperforming Swedish office peers '25e P/CEPS ~14...
Redeye remains confident on the case despite some near-term uncertainty as the market climate contin...
Redeye updates on Better Collective following preliminary Q3-results which were significantly weaker...
Ahead of Taaleri's Q3 results due on 5 November, we lift our 2024 EBIT estimate by 22% to reflect th...
Redeye lowers its fair value range following a reconsideration of its financial estimates (following...
Net sales of EUR 112m was well above our expectation (EUR 91m) in Q3.
Redeye keeps its Base Case despite cutting its 2024-2025 EBIT forecasts following a Q3 report with s...
Loihde reports its Q3 business report on October 30th.
Consti’s Q3/24 figures were in line with our estimates.
Redeye provides a more in-depth review of Episurf Medical’s Q3 report.
Gapwaves announced a supply agreement and joint development with Valeo (previously undisclosed Europ...
